Research programme: cancer therapy - LiponexAlternative Names: HDC 100
Latest Information Update: 25 May 2008
At a glance
- Originator Liponex
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 May 2008 Preclinical development is ongoing
- 27 Mar 2006 Preclinical trials in Cancer in Canada (unspecified route)